SCHEDULE: Gates Frontier and Bill Gates Disclose 5.6% Stake in Lyell Immunopharma
Beneficial Ownership Report
Gates Frontier, LLC and William H. Gates III have jointly reported a beneficial ownership of 5.6% in Lyell Immunopharma, Inc., totaling 1,040,964 shares of common stock.
Summary
- Gates Frontier, LLC and William H. Gates III have filed a Schedule 13G, reporting beneficial ownership of Lyell Immunopharma, Inc. common stock.
- The reporting persons collectively own 1,040,964 shares of Lyell Immunopharma's common stock.
- This ownership represents 5.6% of the total outstanding shares of Lyell Immunopharma.
- The percentage is calculated based on 14,808,006 shares outstanding as of May 30, 2025, and an additional 3,753,752 shares issued on July 25, 2025, totaling 18,561,758 shares.
- Both Gates Frontier, LLC and William H. Gates III hold sole voting and sole dispositive power over these 1,040,964 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or outlook. It is a neutral, compliance-driven report.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Lyell Immunopharma's future performance or operations.
Industry Context
This Schedule 13G filing indicates a significant passive investment by Gates Frontier, LLC and William H. Gates III in Lyell Immunopharma, a biotechnology company. Such filings are common for institutional investors or high-net-worth individuals who acquire more than 5% of a company's shares for investment purposes, without intending to influence or change control of the issuer. For a biotech company, a notable investor's stake can sometimes be viewed positively, signaling confidence in the company's long-term prospects, although this filing explicitly states no intent to influence control.
Related Party Transactions
- William H. Gates III is the sole member of Gates Frontier, LLC, meaning his beneficial ownership is deemed to include shares held by Gates Frontier, LLC, establishing a related party relationship in terms of beneficial ownership reporting.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a prominent investor like William H. Gates III and Gates Frontier, LLC may be perceived as a vote of confidence, potentially influencing investor sentiment and share price. It also increases transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2008-08-12 | Date of Special Limited Power of Attorney appointing Alan Heuberger attorney-in-fact for William H. Gates III. |
| 2013-10-11 | Date of Special Limited Power of Attorney appointing Alan Heuberger attorney-in-fact for Michael Larson, Manager of Gates Frontier, LLC. |
| 2025-05-30 | Date as of which 14,808,006 shares of Common Stock were reported outstanding in Lyell Immunopharma's Form S-3. |
| 2025-07-18 | Date Lyell Immunopharma's Form S-3 was filed. |
| 2025-07-25 | Date of event which requires filing of this statement; also the date Lyell Immunopharma issued 3,753,752 shares of Common Stock as reported on Form 8-K. |
| 2025-08-01 | Date the Schedule 13G was signed by Gates Frontier, LLC and William H. Gates III. |
Keywords
Lyell Immunopharma, Gates Frontier, William H. Gates III, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Immunotherapy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.